Your browser doesn't support javascript.
loading
The vaccinia virus based Sementis Copenhagen Vector vaccine against Zika and chikungunya is immunogenic in non-human primates.
Prow, Natalie A; Liu, Liang; McCarthy, Mary K; Walters, Kevin; Kalkeri, Raj; Geiger, Jillian; Koide, Fusataka; Cooper, Tamara H; Eldi, Preethi; Nakayama, Eri; Diener, Kerrilyn R; Howley, Paul M; Hayball, John D; Morrison, Thomas E; Suhrbier, Andreas.
Affiliation
  • Prow NA; Inflammation Biology, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4029 Australia.
  • Liu L; Australian Infectious Disease Research Centre, Brisbane, QLD 4029 and 4072 Australia.
  • McCarthy MK; Experimental Therapeutics Laboratory, School of Pharmacy and Medical Sciences, UniSA Cancer Research Institute, University of South Australia, Adelaide, SA 5000 Australia.
  • Walters K; Experimental Therapeutics Laboratory, School of Pharmacy and Medical Sciences, UniSA Cancer Research Institute, University of South Australia, Adelaide, SA 5000 Australia.
  • Kalkeri R; Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO 80045 USA.
  • Geiger J; Department of Infectious Disease Research, Southern Research Institute, Frederick, MD 21701 USA.
  • Koide F; Department of Infectious Disease Research, Southern Research Institute, Frederick, MD 21701 USA.
  • Cooper TH; Department of Infectious Disease Research, Southern Research Institute, Frederick, MD 21701 USA.
  • Eldi P; Department of Infectious Disease Research, Southern Research Institute, Frederick, MD 21701 USA.
  • Nakayama E; Experimental Therapeutics Laboratory, School of Pharmacy and Medical Sciences, UniSA Cancer Research Institute, University of South Australia, Adelaide, SA 5000 Australia.
  • Diener KR; Experimental Therapeutics Laboratory, School of Pharmacy and Medical Sciences, UniSA Cancer Research Institute, University of South Australia, Adelaide, SA 5000 Australia.
  • Howley PM; Inflammation Biology, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4029 Australia.
  • Hayball JD; Department of Virology I, National Institute of Infectious Diseases, Tokyo, 162-8640 Japan.
  • Morrison TE; Experimental Therapeutics Laboratory, School of Pharmacy and Medical Sciences, UniSA Cancer Research Institute, University of South Australia, Adelaide, SA 5000 Australia.
  • Suhrbier A; Robinson Research Institute and Adelaide Medical School, University of Adelaide, Adelaide, SA 5005 Australia.
NPJ Vaccines ; 5(1): 44, 2020.
Article in En | MEDLINE | ID: mdl-32550013
ABSTRACT
The Sementis Copenhagen Vector (SCV) is a new vaccinia virus-derived, multiplication-defective, vaccine technology assessed herein in non-human primates. Indian rhesus macaques (Macaca mulatta) were vaccinated with a multi-pathogen recombinant SCV vaccine encoding the structural polyproteins of both Zika virus (ZIKV) and chikungunya virus (CHIKV). After one vaccination, neutralising antibody responses to ZIKV and four strains of CHIKV, representative of distinct viral genotypes, were generated. A second vaccination resulted in significant boosting of neutralising antibody responses to ZIKV and CHIKV. Following challenge with ZIKV, SCV-ZIKA/CHIK-vaccinated animals showed significant reductions in viremias compared with animals that had received a control SCV vaccine. Two SCV vaccinations also generated neutralising and IgG ELISA antibody responses to vaccinia virus. These results demonstrate effective induction of immunity in non-human primates by a recombinant SCV vaccine and illustrates the utility of SCV as a multi-disease vaccine platform capable of delivering multiple large immunogens.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: NPJ Vaccines Year: 2020 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: NPJ Vaccines Year: 2020 Document type: Article
...